Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
暂无分享,去创建一个
[1] J. Hubble,et al. Pramipexole in patients with early Parkinson's disease. , 1995, Clinical neuropharmacology.
[2] M. E. Lajiness,et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. , 1995, European journal of pharmacology.
[3] Cumming Ms. Blisters, beetles, and beliefs. , 1995 .
[4] P. Jenner,et al. The rationale for the use of dopamine agonists in Parkinson's disease , 1995, Neurology.
[5] C. Vedeler,et al. Receptors for gammaglobulin in the central and peripheral nervous system. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[6] G. Broe,et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[7] J. Kebabian,et al. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. , 1993, The Journal of pharmacology and experimental therapeutics.
[8] G. Pöch,et al. Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil. , 1992, European journal of pharmacology.
[9] A. Lieberman. Dopamine agonists used as monotherapy in de novo PD patients: Comparisons with selegiline , 1992, Neurology.
[10] W. Hauser. Status epilepticus: Epidemiologic considerations , 1990, Neurology.
[11] Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[12] R. Riopelle,et al. A Comparison of Bromocriptine (Parlodel®) and Levodopa-Carbidopa (Sinemet®) For Treatment of “De Novo” Parkinson's Disease Patients , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[13] U. Rinne. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease , 1987, Neurology.
[14] E. Tolosa,et al. Low‐Dose Bromocriptine in the Early Phases of Parkinson's Disease , 1987, Clinical neuropharmacology.
[15] W. J. Chen,et al. Renal histology and clinical features of patients with systemic lupus erythematosus. , 1987, Changgeng yi xue za zhi.
[16] R. Elton,et al. Bromocriptine: long-term low-dose therapy in Parkinson's disease. , 1986, Clinical neuropharmacology.
[17] S. Chu,et al. Application of cyclosporin A in renal transplant recipients. Preliminary report. , 1986, Changgeng yi xue za zhi.
[18] D. J. Kamphuis,et al. Low‐dose bromocriptine therapy in Parkinson's disease , 1986, Neurology.
[19] Y. Mizuno,et al. Pergolide in the treatment of Parkinson's disease , 1984, Neurology.
[20] J. Montastruc,et al. Long-term treatment of Parkinson's disease with bromocriptine. , 1979, Journal of neurology, neurosurgery, and psychiatry.
[21] V. Logue. Angiomas of the spinal cord: review of the pathogenesis, clinical features, and results of surgery. , 1979, Journal of neurology, neurosurgery, and psychiatry.
[22] P. Strange. Dopamine receptors in the basal ganglia: Relevance to parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[23] U. Rinne. Early dopamine agonist therapy in Parkinson's disease , 1989, Movement disorders : official journal of the Movement Disorder Society.
[24] A. Lees,et al. Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease. , 1987, Advances in neurology.
[25] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[26] P. M. L. Quesne. Toxic substances and the nervous system: the role of clinical observation. , 1981 .